BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 22706011)

  • 21. Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial.
    Zolla-Pazner S; Gilbert PB
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thailand's Prime-Boost HIV Vaccine Phase III.
    Trinvuthipong C
    Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of adenovirus in vaccines for HIV.
    Patterson S; Papagatsias T; Benlahrech A
    Handb Exp Pharmacol; 2009; (188):275-93. PubMed ID: 19031031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic carbohydrate-based HIV-1 vaccines.
    Bastida I; Fernández-Tejada A
    Drug Discov Today Technol; 2020 Dec; 35-36():45-56. PubMed ID: 33388127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition.
    Singh A; Permar S; Kollmann TR; Levy O; Marovich M; De Paris K
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31315966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 28. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 29. Current issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists.
    Sahloff EG
    Pharmacotherapy; 2005 May; 25(5):741-7. PubMed ID: 15899735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
    Walker LM; Burton DR
    Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poxvirus vector-based HIV vaccines.
    Pantaleo G; Esteban M; Jacobs B; Tartaglia J
    Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV/AIDS Vaccines: 2018.
    Robinson HL
    Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 37. Progress in the rational design of an AIDS vaccine.
    Nabel GJ; Kwong PD; Mascola JR
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.
    Bonsignori M; Alam SM; Liao HX; Verkoczy L; Tomaras GD; Haynes BF; Moody MA
    Trends Microbiol; 2012 Nov; 20(11):532-9. PubMed ID: 22981828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.